Sleep alterations in an environmental neurotoxin-induced model of parkinsonism

Experimental Neurology

Volumn 226, Issue 1, 2010, Pages 84-89

  McDowell, Kimberly A ^a   Hadjimarkou, Maria M ^a,c   Viechweg, Shaun ^a   Rose, Avigail E ^a   Clark, Sarah M ^a   Yarowsky, Paul J ^a,b   Mong, Jessica A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CYPRUS   (Cyprus)

Author keywords

Cycad; Excessive daytime sleepiness; Orexin; Parkinson's disease

Indexed keywords

NEUROTOXIN; OREXIN A; HYPOPHYSIS HORMONE; HYPOTHALAMUS HORMONE; MELANIN; MELANIN-CONCENTRATING HORMONE; NEUROPEPTIDE; OREXINS; PROTEIN C FOS; SIGNAL PEPTIDE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYCAS; CYCAS MICRONESICA; DIETARY INTAKE; FLOUR; HYPOTHALAMUS; MALE; NEUROPATHOLOGY; NONHUMAN; NONREM SLEEP; PARKINSONISM; PLANT SEED; PRIORITY JOURNAL; RAT; REM SLEEP; SLEEP DISORDER; SLEEP PATTERN; SLEEP TIME; SOMNOLENCE; WAKEFULNESS; ANIMAL; AROUSAL; BIOSYNTHESIS; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; ENVIRONMENTAL EXPOSURE; IMMUNOHISTOCHEMISTRY; NERVE DEGENERATION; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; SLEEP; SPRAGUE DAWLEY RAT; STATISTICAL ANALYSIS; SYNAPTIC TRANSMISSION; TOXICITY;

ANIMALS; AROUSAL; CYCAS; DATA INTERPRETATION, STATISTICAL; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; ENVIRONMENTAL EXPOSURE; HYPOTHALAMIC HORMONES; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MELANINS; NERVE DEGENERATION; NEUROPEPTIDES; NEUROTOXINS; PARKINSON DISEASE, SECONDARY; PITUITARY HORMONES; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; SEEDS; SLEEP; SLEEP, REM; SYNAPTIC TRANSMISSION;

EID: 77957819556     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.08.005     Document Type: Article

References (26)

1. Abbott R.D., Ross G.W., White L.R., et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005, 65:1442-1446.
2. Arnulf I., Konofal E., Merino-Andreu M., et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002, 58:1019-1024.
3. Barraud Q., Lambrecq V., Forni C., et al. Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp. Neurol. 2009, 219(2):574-582.
4. Baumann C.R., Bassetti C.L. Hypocretins (orexins) and sleep-wake disorders. Lancet Neurol. 2005, 4:673-682. Review.
5. Carlsson A., Lindqvist M., Magnusson T. 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957, 180:1200.
6. Chen L., Thakkar M.M., Winston S., et al. REM sleep changes in rats induced by siRNA-mediated orexin knockdown. Eur. J. Neurosci. 2006, 24:2039-2048.
7. de Lecea L., Kilduff T.S., Peyron C., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl Acad. Sci. USA 1998, 95:322-327.
8. Dhawan V., Healy D.G., Pal S., Chaudhuri K.R. Sleep-related problems of Parkinson's disease. Age Ageing 2006, 35:220-228. Review.
9. El-Ad B., Korczyn A.D. Disorders of excessive daytime sleepiness-an update. J. Neurol. Sci. 1998, 53:192-202. Review.
10. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
11. Friedman J.H., Millman R.P. Sleep disturbances and Parkinson's disease. CNS Spectr. 2008, 13(Supp 4):12-17. Review.
12. Fronczek R., Overeem S., Lee S.Y., et al. Hypocretin (orexin) loss and sleep disturbances in Parkinson's disease. Brain 2007, 130(Pt6):1577-1585.
13. Gerashchenko D., Blanco-Centurion C., Greco M.A., Shiromani P.J. Effects of lateral hypothalamic lesion with the neurotoxin hypocretin-2-saporin on sleep in Long-Evans rats. Neuroscience 2003, 116:223-235.
14. Happe S. Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management. Drugs 2003, 63:2725-2737. Review.
15. Kremer H.P., Bots G.T. Lewy bodies in the lateral hypothalamus: do they imply neuronal loss?. Mov. Disord. 1993, 8:315-320.
16. Langston J.W., Forno L.S. The hypothalamus in Parkinson disease. Ann. Neurol. 1978, 3:129-133.
17. Rao S.D., Banack S.A., Cox P.A., Weiss J.H. BMAA selectively injures motor neurons via AMPA/kainate receptor activation. Exp. Neurol. 2006, 201(1):244-252.
18. Rye D.B. Excessive daytime sleepiness and unintended sleep in Parkinson's disease. Curr. Neurol. Neurosci. Rep. 2006, 6:169-176. Review.
19. Sacks O. The island of the colour-blind and Cycad-island 1996, Picador, London, 120.
20. Sakurai T. Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. Sleep Med. Rev. 2005, 9:231-241. Review.
21. Saper C.B., Chou T.C., Scammell T.E. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 2001, 24:726-731. Review.
22. Shen W.B., McDowell K.A., Siebert A.A., Clark S.M., Dugger N.V., Valentino K.M., Jinnah H.A., Sztalryd C., Fishman P.S., Shaw C.A., Jafri M.S., Yarowsky P.J. Environmental neurotoxin-induced progressive model of parkinsonism in rats. Ann. Neurol. 2010, 68(1):70-80.
23. Stamey W., Jankovic J. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist 2008, 14:89-99. Review.
24. Thannickal T.C., Lai Y.Y., Siegel J.M. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007, 130:1586-1595.
25. Yasui K., Inoue Y., Kanbayashi T., et al. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J. Neurol. Sci. 2006, 250:120-123.
26. Yi P.L., Tsai C.H., Lu M.K., Liu H.J., Chen Y.C., Chang F.C. Interleukin-1beta mediates sleep alteration in rats with rotenone-induced parkinsonism. Sleep 2007, 30:413-425.